Allegro Diagnostics

Category Archives

Veracyte Announces Data Supporting Use of the Percepta™ Bronchial Genomic Classifier to Be Presented at CHEST 2015

SOUTH SAN FRANCISCO, Calif., Oct. 20, 2015 /PRNewswire/ -- Veracyte, Inc. (VCYT), a molecular diagnostics company pioneering the field of molecular cytology, Read more...

New England Journal of Medicine Publishes Study Results Suggesting Veracyte’s Percepta™ Bronchial Genomic Classifier Can Reduce Unnecessary Invasive Procedures in Lung Cancer Diagnosis

South San Francisco, Calif., Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced Read more...

Veracyte Initiates Launch of Percepta™ Bronchial Genomic Classifier

South San Francisco, Calif. - Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostic company pioneering the field of molecular cytology, today announced Read more...

Veracyte, Inc. to Acquire Allegro Diagnostics, Accelerating Entry Into Pulmonology Market

Veracyte, Inc. VCYT a molecular diagnostics company pioneering the field of molecular cytology, today announced an agreement to acquire Allegro Diagnostics Read more...

Allegro Diagnostics Confirms Clinical Validation of BronchoGen™ Genomic Test for Improved Diagnosis of Lung Cancer in AEGIS-2 Clinical Trial

Allegro Diagnostics Corp. today announced that the AEGIS-2 clinical trial has met its primary endpoint, demonstrating that the BronchoGen™ genomic test Read more...

Allegro Diagnostics to Present Analytical Validation of BronchoGen at ATS International Conference

Maynard, Mass., May 17, 2013—Allegro Diagnostics today announced its participation in the American Thoracic Society International Conference, being Read more...

Allegro Diagnostics to Present at the Oncology Biomarkers Conference

Maynard, Mass., March 18, 2013—Allegro Diagnostics today announced its participation in the Oncology Biomarkers Conference, part of GTC’s Biomarker Read more...

Allegro Diagnostics Announces BronchoGen™ Genomic Test for Improved Diagnosis of Lung Cancer Successfully Achieves Clinical Validation

- BronchoGen Test to Become Available to Patients and Physicians in 2013 - Maynard, Mass., March 12, 2013 – Allegro Diagnostics today announced that Read more...

Allegro Diagnostics Presents Positive AEGIS I Trial Results of BronchoGen™

Allegro Diagnostics Presents Positive AEGIS I Trial Results of BronchoGen™ Genomic Test to Improve Diagnosis of Lung Cancer at Annual CHEST Meeting -- Read more...

Allegro Diagnostics to Present Clinical Trial Results of BronchoGen™ Genomic Test to Improve Diagnosis of Lung Cancer in Late-Breaking Abstract Session at CHEST 2012

-- Confirmatory AEGIS II Study Recently Completed Enrollment -- Maynard, MA, August 27, 2012. Allegro Diagnostics today announced that results from its Read more...

Page 1 of 3123

Contact Info

info@catalysthealthventures.com

(781) 228-5228

50 Braintree Hill Office Park
Suite 301
Braintree, MA 02184